PeptideStack
5.2kquestions
20kanswers
220users

How long does a GLP-1 receptor agonist stay within specification at 2–8 °C once reconstituted?

Asked 21 Jan 2025Modified 15 months agoViewed 44k times
37

Details up front: a GLP-1 receptor agonist · 2–8 °C.

I can find plenty of assertions about this and almost no reasoning, which is usually a sign that nobody has checked.

Assume no laboratory access beyond what I can pay a third party for.

Which parts of this are load-bearing and which parts are habit?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
shelf-life
shelf-life

How long a preparation remains within specification: labelled expiry for a sealed lyophilised vial, beyond-use dating after reconstitution, and…

327 questions
shareeditfollowflag
CF
askedclaudia_ferrante22k2721 Jan 2025
6Worth saying whether the vial has been opened, because that starts a different clock. – u100_marks 3 days ago
add a comment

5 Answers

Sorted by votes
4

Whatever the refrigerated figure is, divide it by about 1. 2–8 °C is the condition the rule of thumb is anchored to, so it is the baseline rather than a multiplier: everything else in this thread is quoted relative to it. So a preparation with a twenty-eight day refrigerated figure has roughly 28 days at 2–8 °C on the same assumption — an order-of-magnitude answer, not a shelf life, and it says nothing about sterility, which has its own clock. "Within specification" also needs a specification: purity, content, or both, and at what limit. Without that the question has no numerical answer at all.

Answer first: the degradation pathways worth knowing are hydrolysis, deamidation, oxidation, aggregation and adsorption, and each has a different trigger and a different mitigation.

Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.

Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.

Cold, dry, dark, still. Those four words cover most of the mitigation.

shareimprove this answerflag
TO
answeredt_oyelaran79k4812 Feb 2025
7Adding for future readers: the domestic leg after delivery is the part you control. – j_wierzbicki 16 days ago
6I have kept vials both ways for a year and this matches what I saw. – Dr_Sara_Kuusela 9 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
4

Asparagine and glutamine are the deamidation risk, and methionine is the oxidation risk.

Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.

At dilute concentrations, suspect adsorption before you suspect chemistry.

shareimprove this answerflag
DF
answeredDr_Colm_Fitzhenry69k24723 Feb 2025
4

Start with the sequence, because which pathways are available depends on which residues are present.

Adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

Metal-catalysed oxidation of methionine is documented across peptide and protein formulations and is why chelators appear in some formulations.

Swirl, never shake. Aggregation is a handling problem more than a time problem.

edited 25 Mar 2025 by rukhsana_iqbal — fixed an arithmetic slip in the third paragraph

shareimprove this answerflag
RI
answeredrukhsana_iqbal17k376 Mar 2025
4

The honest answer is that most reported "degradation" is adsorption and dilution error rather than chemistry.

Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.

Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.

The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.

A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.

shareimprove this answerflag
DW
answereddeamidation_watch45k5817 Mar 2025
4

The short version: water enables most of it, oxygen enables oxidation, surfaces enable adsorption, and agitation enables aggregation.

Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.

Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.

Sequence decides which pathways are even available. Check the residues.

shareimprove this answerflag
VR
answeredv_ramaswamy68k579 May 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.